Right Heart Catheterization

Definition

Right heart catheterization (RHC) is an invasive haemodynamic procedure using a balloon-tipped pulmonary artery catheter (introduced by Swan and Ganz in 1970) to directly measure intracardiac and pulmonary pressures and cardiac output. It is the gold standard for diagnosing and classifying pulmonary hypertension, and plays a pivotal role across the heart failure spectrum — from ambulatory chronic HF to cardiogenic shock, LVAD candidacy, and heart transplantation evaluation.

Key Concepts

Methodology and Technical Standards

Body position and access

• Patient must be supine; any deviation (semi-supine, legs raised) drastically alters pressure and CO measurements. (sources/rhc-hf-ehj-2025, rating: high)
• Preferred access: right internal jugular vein under ultrasound guidance (reduces bleeding complications); femoral vein is an alternative but associated with higher infection risk, need for fluoroscopy, and post-procedural bedrest. (sources/rhc-hf-ehj-2025, rating: high)

Zero-reference

• Mid-thoracic level = level of the left atrium in most patients; must be used for zero-reference. (sources/rhc-hf-ehj-2025, rating: high)
• Every 1 cm deviation changes measured pressure by ~0.8 mmHg — critically important for PAWP. (sources/rhc-hf-ehj-2025, rating: high)

Cardiac output measurement

• Direct Fick = gold standard; requires direct O₂ consumption measurement (Douglas bag or metabolic cart — not widely available). (sources/rhc-hf-ehj-2025, rating: high)
• Thermodilution: inject 10 mL saline at known temperature; average 3 consistent values within 10% of each other; performing injections at the same respiratory phase improves precision; remains accurate even in the presence of tricuspid regurgitation — contrary to common belief; unreliable in intracardiac shunts or ECMO. (sources/rhc-hf-ehj-2025, rating: high) (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Indirect Fick: confirmed inaccurate — demonstrated inaccurate in numerous studies; formulae derived from infants/children or highly selected healthy adults do not reflect contemporary cardiac patients; thermodilution is preferred over indirect Fick. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• During exercise: Indirect Fick cannot be estimated during exercise (PA saturation falls with exercise oxygen uptake in ways not captured by fixed formulae); use direct Fick (metabolic cart) or thermodilution. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Cardiac MRI with quantitative blood flow gating: reliable alternative in shunts or severe TR. (sources/rhc-hf-ehj-2025, rating: high)
• Cardiac index (CI) = CO/BSA; preferred over CO in clinical use. (sources/rhc-hf-ehj-2025, rating: high)
• CO overestimation → underestimates PVR (may incorrectly exclude PAH diagnosis); CO underestimation → overestimates PVR (may incorrectly label patients as PAH). (sources/rhc-hf-ehj-2025, rating: high)

Procedural preparation

• Fasting not required; continue prescribed medications; defer IV sedation — alters breathing patterns and vascular tone, distorting target hemodynamic measures. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Topical/local anaesthesia preferred; oral premedication if anxiolysis required. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Avoid automated monitor average pressure displays — algorithms do not account for respiration or ectopy. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

PAWP timing specifics

• Sinus rhythm: measure at end-diastole (mean of the a-wave); avoid measurement during/after ectopic beats. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Atrial fibrillation: measure PAWP 130–160 ms after QRS onset, before the V-wave. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Saturation verification: discard first 5–10 mL when wedged; saturation within 3–5% of systemic pulse oximetry confirms correct wedge position. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• V-waves (significant AV regurgitation or non-compliant atria): use mean PAWP (including V-waves) for PVR calculations; use mean PAWP excluding V-waves to estimate ventricular end-diastolic pressure. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

Transducer zeroing — upright exercise

• Level at the phlebostatic axis (intersection of 4th intercostal space and mid-chest); mark the RA level on the chest wall fluoroscopically before patient moves upright. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

Respiratory cycle and pressure readings

• All pressures measured at end-expiration, without breath-holding or Valsalva. (sources/rhc-hf-ehj-2025, rating: high)
• Patients with large respiratory swings (COPD, obesity, mechanical ventilation, hyperventilation): average over 3–4 respiratory cycles, or report both end-expiratory and average values. (sources/rhc-hf-ehj-2025, rating: high) (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

PAWP measurement (critical pitfalls)

• Measure just prior to the C-wave in the cardiac cycle — closest approximation to LVEDP. (sources/rhc-hf-ehj-2025, rating: high)
• If C-wave indeterminate: gate to QRS complex (valid only when no large V-waves). (sources/rhc-hf-ehj-2025, rating: high)
• Large V-waves (severe MR, poor LA compliance, VSD): use mean PAWP instead of end-diastolic PAWP. (sources/rhc-hf-ehj-2025, rating: high)
• Atrial fibrillation: may overestimate PAWP vs LVEDP; consider direct LVEDP measurement if implausible. (sources/rhc-hf-ehj-2025, rating: high)
• Two rules of thumb: (1) PAWP must be ≤ diastolic PAP; (2) clear A- and V-waves must be visible. (sources/rhc-hf-ehj-2025, rating: high)
• Over-wedging (balloon over-inflated): loss of A- and V-waves, artificially high PAWP; deflate balloon, retract into RV, re-advance. (sources/rhc-hf-ehj-2025, rating: high)
• Oximetry in wedged position (within 5% of systemic saturation) confirms correct PAWP position. (sources/rhc-hf-ehj-2025, rating: high)

Volume status and diuresis

• Post-diuresis: PAWP may be falsely low → PVR overestimated → may incorrectly diagnose pre-capillary PH. (sources/rhc-hf-ehj-2025, rating: high)
• Volume overloaded / decompensated state: PAWP may be falsely elevated due to ventricular interdependence (severe RV failure → pericardial restraint → raises PAWP, mimicking isolated post-capillary PH). (sources/rhc-hf-ehj-2025, rating: high)
• Ideal: perform RHC in euvolemic state; diurese decompensated patients first. (sources/rhc-hf-ehj-2025, rating: high)

Mixed venous oxygen saturation

• Sampled from the PA at RHC; >75% should prompt stepwise oximetry run to exclude left-to-right shunt. (sources/rhc-hf-ehj-2025, rating: high)
• Decreased in progressive cardiogenic shock (Stages C–E); increased in late-stage septic shock. (sources/rhc-hf-ehj-2025, rating: high)

Safety

• Serious adverse events: ~1.1%; procedure-related mortality: ~0.055% in experienced PH centres. (sources/rhc-hf-ehj-2025, rating: high)
• Most feared complication: PA perforation. Relative contraindications include RV/RA thrombus or tumour, recent pacemaker (<1 month), mechanical right heart valve, TriClip. (sources/rhc-hf-ehj-2025, rating: high)

Haemodynamic Variables

(sources/rhc-hf-ehj-2025, rating: high)

PAWP Thresholds and Zone of Uncertainty

Normal PAWP

• Meta-analysis of n=940 healthy subjects: upper limit of normal PAWP = 13 mmHg (independent of BMI or age; women slightly higher than men). (sources/rhc-hf-ehj-2025, rating: high)
• Historical context: originally set at 10–11 mmHg (1973 WHO); raised to 15 mmHg with introduction of PAH trials in the 1990s. (sources/rhc-hf-ehj-2025, rating: high)
• Current ESC PH guidelines threshold for post-capillary PH: PAWP >15 mmHg. (sources/rhc-hf-ehj-2025, rating: high)

Zone of uncertainty (12–18 mmHg)

• PAWP in the range ~12–18 mmHg should be contextualised to individual clinical probability of left heart disease rather than treated as definitive. (sources/rhc-hf-ehj-2025, rating: high)
• Provocative testing should be considered in this zone to uncover latent HFpEF. (sources/rhc-hf-ehj-2025, rating: high)

Provocative testing to unmask HFpEF — standardized protocols

Volume challenge:

• Standard fluid bolus: 7–10 mL/kg (~500 mL) of 0.9% saline at ≥100 mL/min; or passive leg raise (PLR) at ~45° or "feet on pedals"
• Complete hemodynamic measurements 20 seconds to 3 minutes after completion
• Expected normal response: RAP +5 mmHg, PAWP +6 mmHg, mPAP +7–8 mmHg; CO +1.5–2 L (primarily stroke volume, not heart rate); elderly (especially older women) show steeper responses
• PAWP ≥19 mmHg after fluid bolus or PLR = occult postcapillary PH (excellent PPV; single-centre data — awaiting multicenter validation; updated from earlier ≥18 mmHg threshold) (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• PLR with PAWP ≤11 mmHg = postcapillary PH ruled out (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• High proportion of intermediate results (PAWP 12–18 mmHg) limits diagnostic utility in many patients; results must be interpreted with clinical phenotype and imaging (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Earlier fluid challenge threshold: PAWP ≥18 mmHg suggested HFpEF (lacks long-term validation). (sources/rhc-hf-ehj-2025, rating: high)

Exercise RHC — HFpEF invasive diagnostic criteria (Table 4 — at least ONE required):

1. Resting PAWP ≥15 mmHg
2. PAWP ≥20 mmHg with fluid bolus or passive leg raise
3. Peak exercise PAWP ≥25 mmHg (supine) OR ≥20 mmHg (upright)
4. PAWP/CO slope >2 mmHg·L·min (regardless of body position)
   (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

Exercise-induced PH: mPAP/CO slope >3 mmHg·L·min; predicts outcomes independently from resting haemodynamics; both precapillary and postcapillary components can contribute; may unmask postcapillary PH in presumed precapillary PH (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

Additional exercise phenotypes:

• Chronotropic incompetence: HRR <0.80 (or <0.62 on beta-blockers); HRR = (peak HR − rest HR) / (predicted peak HR − rest HR); predicted peak HR = 220 − age (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Preload insufficiency: Peak VO₂ <80% + peak CO <80% + ΔPAWP <7 mmHg during exercise (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• PCWL (PAWP indexed to workload/body weight): >25.5–34.7 mmHg·W·kg = higher mortality risk in HFrEF and HFpEF (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

Supine vs upright: supine yields higher venous return + stable measurements + validated with dapagliflozin; upright better replicates daily activities, higher workload, more repeated measures; PAWP/CO slope (not absolute PAWP) consistently differentiates HFpEF from controls in both positions (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

• RV-PA coupling (conductance catheter): Volume-pressure loops of RV at rest; mPAP/CO slope elevation identifies early pre-capillary PH; also assessable non-invasively via TAPSE/sPAP ratio. (sources/rhc-hf-ehj-2025, rating: high)

RHC in Chronic Heart Failure

PH classification by haemodynamics

• Pre-capillary PH: PAWP ≤15 mmHg + PVR >2 WU (typical in PAH, CTEPH, lung disease)
• Isolated post-capillary PH: PAWP >15 mmHg + PVR ≤2 WU
• Combined pre- and post-capillary PH: PAWP >15 mmHg + PVR >2 WU

Chronic HF haemodynamic phenotypes (sources/rhc-hf-ehj-2025, rating: high)

• Bi-ventricular HF (typical): mPAP ~25–35 mmHg, PAWP >15 mmHg, RAP >8 mmHg, PVR 2–5 WU, mild-to-moderate RV dysfunction
• Right heart predominant left HF (severe phenotype): mPAP >35 mmHg, PAWP >15 mmHg, RAP >12 mmHg, PVR >5 WU (may be lower post-diuresis), CI <2.2 L/min/m², severe TR, severe RV failure, cardio-hepato-renal syndrome

Constrictive pericarditis vs restrictive cardiomyopathy (sources/rhc-hf-ehj-2025, rating: high)

• Both: RAP:PAWP ratio >0.5
• Constrictive pericarditis: RAP↑ + PAWP↓ discordantly during inspiration (enhanced ventricular interdependence)
• Restrictive cardiomyopathy: concordant RAP and PAWP changes during respiration; diastolic flow reversal into hepatic vein with inspiration
• Simultaneous right + left heart catheterisation often required; cardiac MRI as alternative if invasive procedure contraindicated

Guideline recommendations (chronic HF)

• ESC Class 2a: HF thought due to constrictive pericarditis, restrictive CMP, congenital HD, high-output states
• ESC Class 2b: May be considered to confirm HFpEF diagnosis in selected patients (may change diuretic or SGLT2i therapy)
• ESC Class 2b: Wireless PAP monitoring (CHAMPION trial: 33% reduction in HF hospitalisations)
• AHA Class 3: Routine RHC does not provide sufficient information to guide treatment decisions (sources/rhc-hf-ehj-2025, rating: high)

RHC in Valvular Heart Disease

• ESC: RHC reserved for inconclusive or discordant non-invasive evaluation; if sPAP >50 mmHg is the only surgical criterion, RHC confirmation required. (sources/rhc-hf-ehj-2025, rating: high)
• Severe TR: Doppler gradients may underestimate PH severity; RHC with PVR assessment recommended. (sources/rhc-hf-ehj-2025, rating: high)
• Severe primary MR: RHC to confirm PH (sPAP >50 mmHg) when this is the sole criterion for surgical referral. (sources/rhc-hf-ehj-2025, rating: high)
• Mitral stenosis: AHA Class 1 for RHC at rest and during exercise; direct pressure gradient when imaging is inadequate. (sources/rhc-hf-ehj-2025, rating: high)
• Aortic stenosis: RHC gold standard for PH diagnosis; PH is a strong mortality predictor in severe AS; improves prognostic power over echocardiography alone. (sources/rhc-hf-ehj-2025, rating: high)

RHC in Acute Heart Failure

Diamond-Forrester classification (1973)

• Warm/cold based on CI cut-off 2.5 L/min/m²; wet/dry based on PAWP cut-off 18 mmHg
• Still used but ESC 2021 prefers clinical phenotype classification (acute decompensation, pulmonary oedema, isolated RV failure, cardiogenic shock). (sources/rhc-hf-ehj-2025, rating: high)

Acute HF haemodynamic phenotypes (sources/rhc-hf-ehj-2025, rating: high)

• Bi-ventricular failure hallmark: RAP:PAWP >0.5 (sources/rhc-hf-ehj-2025, rating: high)

RHC in Cardiogenic Shock

SCAI shock stages and RHC variables (sources/rhc-hf-ehj-2025, rating: high)

• Stages B–E: PAWP >15 mmHg; Stage E: PAWP >20 mmHg
• Stages C–E: CI <2.2 L/min/m²; RAP >10 mmHg
• Mixed venous O₂ saturation: maintained (≥65%) in Stages A+B; decreased in Stages C–E

Isolated RV cardiogenic shock

• RAP strongly elevated (>14 mmHg), PAWP normal/high-normal (<18 mmHg), RAP:PAWP >0.5–0.8, PAPI decreased, CI <2.2 L/min/m²
• Isolated RV infarction: RAP:PAWP ≥0.8 (sources/rhc-hf-ehj-2025, rating: high)

Shock differentiation by RHC (sources/rhc-hf-ehj-2025, rating: high)

Advanced haemodynamics in cardiogenic shock

• PAPI <2.0 and CPO <0.6 Watts: suggest Stage C cardiogenic shock (AHA guidelines)
• Not yet adopted in European guidelines; prognostic value established (sources/rhc-hf-ehj-2025, rating: high)

Timing

• Early RHC (within 2 days): lower AKI incidence (OR 0.69), higher MCS use (OR 1.67), shorter stay vs late RHC (observational data, n=46,963) (sources/rhc-hf-ehj-2025, rating: high)
• RCT investigating early vs usual care RHC in cardiogenic shock is ongoing (NCT05485376) (sources/rhc-hf-ehj-2025, rating: high)

RHC in Heart Transplantation

Pre-listing (Class 1 — ISHLT) (sources/rhc-hf-ehj-2025, rating: high)

• RHC required prior to listing; repeated every 3–6 months until transplantation
• PAWP >18 mmHg independently associated with waitlist death, delisting, urgent HTX, and LVAD implantation (French national registry, n=837)
• PVR >2.5 WU independently associated with increased post-HTX mortality (n=26,649)

Prohibitive PH thresholds for HTX

• sPAP ≥50 mmHg + (TPG ≥15 mmHg or PVR ≥3 WU) = prohibitive PH → vasodilator challenge required (sources/rhc-hf-ehj-2025, rating: high)

Vasodilator challenge (nitroprusside or milrinone)

• Acceptable response: TPG ≤12–15 mmHg + PVR ≤2.5–3 WU + systolic BP >85 mmHg → listing permitted
• If PVR reversible but BP <85 mmHg: RV failure risk remains high
• If challenge fails: hospitalisation + diuresis/vasoactive therapy → temporary MCS → durable LVAD
• LVADs can improve/reverse PH; if PH persists after 3–6 months of effective LV unloading → considered irreversible → HTX precluded (sources/rhc-hf-ehj-2025, rating: high)

Post-HTX RHC

• Grade 3 cardiac allograft vasculopathy (75% 5-year mortality): restrictive physiology on RHC (RAP:PAWP >0.5) is part of diagnostic work-up; may inform re-transplantation decision (sources/rhc-hf-ehj-2025, rating: high)

RHC in LVAD

Candidacy criteria (among other factors) (sources/rhc-hf-ehj-2025, rating: high)

• PAWP ≥20 mmHg + systolic BP ≤90 mmHg, or CI ≤2.0 L/min/m²

Pre-implantation goals (sources/rhc-hf-ehj-2025, rating: high)

• RAP ≤12–15 mmHg before surgery (minimises RV overload)
• RHC within 1–2 weeks for elective cases; or pre-operatively in ICU

RV failure predictors post-LVAD (sources/rhc-hf-ehj-2025, rating: high)

• RAP >15 mmHg + RAP/PAWP >0.63: 1-year survival 59% vs 78%
• PAPI <1.85: 95% sensitivity for post-LVAD RV failure; outperforms RAP, RAP:PAWP, RVSWI
• RVSWI and RAP: best parameters to identify risk of post-LVAD RV failure

Post-implantation ramp test (sources/rhc-hf-ehj-2025, rating: high)

• Combined echo + RHC at varying LVAD speeds
• Target: RAP <12 mmHg + PAWP <18 mmHg; intermittent aortic valve opening; minimal MR
• Detects LVAD thrombosis; shown to improve outcomes and functional status

LVAD explantation (myocardial recovery — Class 2a) (sources/rhc-hf-ehj-2025, rating: high)

• CI >2.6 L/min/m² + RAP <10 mmHg + PAWP <13 mmHg confirmed during serial speed reduction / off-pump trials

Vasodilator Challenge for PH Reversibility in Advanced HF

Indications (ISHLT 2024): PASP >50 mmHg + (TPG ≥15 mmHg OR PVR ≥3 WU) — also consider if TPG/PVR elevated with low CO even if PASP <50 mmHg
Hemodynamic targets: TPG ≤12–15 mmHg + PVR ≤2.5–3 WU + SBP >85 mmHg

• Sodium nitroprusside (SNP): Start 0.25–0.5 μg/kg/min; titrate ↑0.5 μg/kg/min every 3–5 min; max 10 μg/kg/min; infusion pump only; light-sensitive bag. Mechanism: SVR reduction → LV afterload reduction → CO↑ + PAWP↓ → secondary PA pressure/PVR reduction. Stop if PAWP <12 mmHg; contraindicated SBP <85 mmHg. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Milrinone: Bolus 25–50 μg/kg over 5–10 min; reassess at 5 min (no uptitration). Mechanism: PDE3 inhibition → enhanced contractility + vasodilation; higher inotropic effect vs SNP; less BP-dependent mechanism for PAWP reduction. Preferred over SNP if: hypotension, low SVR, or PVR elevation driven by low CO. Caution: unstable tachyarrhythmias; eGFR <30 mL/min (prolonged half-life). (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• iNO: Alternative if PAWP not elevated; avoid if PAWP elevated (risk of pulmonary oedema). (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

PAH Acute Vasoreactivity Testing (AVT)

Indication: PAH (idiopathic, heritable, or drug-induced) with mPAP >20 mmHg + PAWP <15 mmHg
Positive response (updated definition): mPAP decrease ≥10 mmHg to absolute value ≤40 mmHg with maintained or increased CO — replaces older 20% PVR reduction criterion (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
Responders: ~10%; predictive/prognostic value only in idiopathic/heritable/drug-induced PAH; long-term CCB responders now have own WSPH subclassification

Preferred: iNO and inhaled prostacyclin analogs (similar response rates; better systemic safety vs IV epoprostenol and adenosine). AVT not recommended in other PH forms. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

Advanced Hemodynamic Metrics

• Cardiac power output (CPO): Reflects LV/RV function; reincorporating RAP into CPO formula improves prognostic value in acute decompensated HF and HF-CS vs older formula. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Aortic pulsatility index (API): LV ejection efficiency and ventriculoarterial coupling; predictor of myocardial recovery and MCS weaning ability; principal components = pulse pressure and PAWP. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• PA pulsatility index (PAPI): Identifies severe RV dysfunction in AMI; predicts RV failure after LVAD. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• RVSWI (RV stroke work index): Beat-to-beat RV workload; prognostic in HF-CS and post-LVAD RV failure. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Myocardial performance score: Combines API + CPO; reflects ventricular power efficiency; correlates with ventriculoarterial coupling and overall energetic state. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

LVAD Hemodynamic Studies

Ramp study (speed optimization):

• Combined echo + invasive hemodynamics required for current centrifugal flow pumps
• Hemodynamic targets: CVP <12 mmHg + PAWP <18 mmHg + CI >2.2 L/min/m²
• Optimization associated with reduced readmissions and hemocompatibility-related adverse events (RAMP-IT-UP trial; HeartMate 3 data)
• CO by thermodilution preferred over estimated Fick in LVAD patients (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

Reverse ramp (recovery assessment):

• Incrementally decrease LVAD speed to nominal flow; hemodynamics at each stage
• Traditional recovery thresholds at nominal flow: PAWP ≤12–15 mmHg + CI ≥2.4–2.6 L/min/m² + MAP ≥65 mmHg
• API may be more prognostic than standard thresholds; stable/rising pulse pressure or persistently low PAWP at nominal flow predicts sustained recovery (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

Remote PA Pressure Monitoring

• Recommended for NYHA II–III HF + recent hospitalisation or elevated natriuretic peptides
• CHAMPION (CardioMEMS): PA-guided management → reduced HF hospitalisations/urgent visits
• GUIDE-HF and MONITOR-HF: Consistent HF hospitalisation reduction across varying ejection fractions
• PROACTIVE-HF (Cordella PA Sensor, Edwards Lifesciences): Significant HF hospitalisation reductions; confirmed safety of seated PA pressure monitoring
• Rising PA pressures often detected days to weeks before clinical congestion — enables proactive diuretic titration and GDMT optimization (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Limited data in PAH specifically (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

Nitric Oxide — Safety Caveat in Vasoreactivity Testing

• Nitric oxide (and adenosine) should only be administered for vasoreactivity testing in patients with elevated mPAP and a normal PAWP sources/hemodynamics-circ-2012 high
• In patients with elevated baseline LAP/PAWP, NO dilates the postcapillary pulmonary bed → further increase in LA filling pressures → risk of acute pulmonary oedema sources/hemodynamics-circ-2012 high

Pulmonary Arterial Capacitance

• Pulmonary artery capacitance (PAC = stroke volume / pulmonary pulse pressure) has additional prognostic value in idiopathic PAH and should be measured at initial catheterization sources/hemodynamics-circ-2012 high
• Decreased PAC is an early marker of pulmonary vascular disease — may identify risk before PVR rises sources/rhc-hf-ehj-2025 high

Future Directions

Non-invasive PAWP assessment (sources/rhc-hf-ehj-2025, rating: high)

• 4D flow CMR: LA blood flow acceleration correlates with invasive PAWP (r=0.94, SD of differences 2 mmHg)
• Lung B-lines ultrasonography: AUC 0.73 for PAWP >15 mmHg; only high B-line index (≥28) is specific
• Left atrial strain (echocardiography): AUC 0.9 for elevated PAWP at rest or exercise; prognostically relevant
• Mitral deceleration rate + LVIVRT + systolic fraction of pulmonary venous flow formula: AUC 0.91, SD 2.7 mmHg

Pulmonary arterial compliance (PAC = SV / pulmonary pulse pressure) (sources/rhc-hf-ehj-2025, rating: high)

• PAC ≥3.0 mL/mmHg associated with improved survival in PH
• Decreased PAC is an early event in pulmonary vascular disease — may identify risk before PVR rises

Contradictions / Open Questions

• ESC vs AHA on routine RHC in chronic HF: ESC Class 2b for selected patients vs AHA Class 3 (routine use not recommended). The divergence reflects different interpretations of observational evidence rather than conflicting data. (sources/rhc-hf-ehj-2025, rating: high)
• PAWP normal threshold: The true physiological upper limit is 13 mmHg (meta-analysis), yet PH guidelines use 15 mmHg as the post-capillary PH threshold, creating a diagnostic grey zone (13–15 mmHg) where clinicians may under-recognise early LHD. (sources/rhc-hf-ehj-2025, rating: high)
• Vasodilator testing in HTX: One US study could not identify a survival benefit with a positive vasodilator test despite PVR reduction to <2.5 WU; another found improved survival. No absolute PVR cut-off endorsed by current guidelines. (sources/rhc-hf-ehj-2025, rating: high)
• Advanced haemodynamics (PAPI, CPO, RVSWI): Prognostic value established; not yet integrated into European practice guidelines for cardiogenic shock staging. (sources/rhc-hf-ehj-2025, rating: high)
• RCT evidence for early RHC in cardiogenic shock: Survival benefit is based on observational data; PACCS RCT (NCT05485376) is ongoing. (sources/rhc-hf-ehj-2025, rating: high) (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Absolute PAWP vs PAWP/CO slope in exercise testing: ~20% discordance between the two criteria in large multicenter studies; absolute PAWP ≥25 mmHg (supine) and PAWP/CO slope >2 identify different patient subgroups with different CO profiles; PAWP/CO slope is more consistently discriminative across studies and body positions, but optimal threshold standardisation is not complete. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Volume challenge threshold — PAWP ≥18 vs ≥19 mmHg: Earlier guidance proposed ≥18 mmHg; this 2026 AHA statement proposes ≥19 mmHg for occult postcapillary PH based on a single-centre study with excellent PPV. Multicenter validation is needed before clinical adoption of either specific threshold. (sources/rhc-hf-ehj-2025, rating: high) (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
• Translating exercise phenotypes into effective interventions: Beta-blocker withdrawal improved peak VO₂ in chronotropic incompetent HFpEF; atrial pacing did not; ivabradine results are mixed. Precise hemodynamic phenotyping has not consistently translated into efficacious targeted therapies. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)

Connections

• Related to entities/Heart-Failure
• Related to entities/Pulmonary-Hypertension
• Related to concepts/HFpEF
• Related to entities/CTEPH
• Related to concepts/Aortic-Stenosis
• Related to concepts/Primary-Mitral-Regurgitation
• Related to concepts/Tricuspid-Regurgitation
• Related to concepts/Mitral-Stenosis
• Related to concepts/RV-PA-Coupling
• Related to concepts/Constrictive-vs-Restrictive — haemodynamic differentiation of constrictive pericarditis vs RCM
• Related to sources/rhc-hf-ehj-2025
• Related to sources/hemodynamic-hf-pht-aha-2026

Sources

• sources/hemodynamic-hf-pht-aha-2026
• sources/hemodynamics-circ-2012
• sources/rhc-hf-ehj-2025